We examined the relation between ERBB2 gene expression (as determined by a real-time quantitative RT-PCR assay) and the response to adjuvant tamoxifen therapy in a well-defined cohort of 125 ER alpha -positive postmenopausal patients with breast cancer. Although ERBB2 overexpression was associated with shorter relapse-free survival in univariate analysis (P = 0.00029), ERBB2 did not persist as an independent prognostic factor in multivariate analysis. Nevertheless, when we analyzed the ERBB2 mRNA level as a continuous variable, the higher the ERBB2RNA level, the poorer the outcome (P = 0.00036). The results point to the need for a quantitative ERBB2 expression assay for use in future studies of ERBB2-based clinical management of breast cancer. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
|Translated title of the contribution||ERBB2 status and benefit from adjuvant tamoxifen in ER alpha-positive postmenopausal breast carcinoma|
|Pages (from-to)||173 - 178|
|Publication status||Published - Dec 2001|
Bibliographical notePublisher: Elsevier Sci Ireland Ltd
Other identifier: IDS Number: 494AH